7 On July 8, the 19th Medicilon symposium "Helping the Sail, Setting Sail for a New Era of Nucleic Acid Drugs" online meeting was successfully held.
This seminar invited leading figures in the field of nucleic acid drug development and research, focusing on nucleic acid drugs. The content covered the entire process of preclinical research of nucleic acid drugs, including drug discovery, pharmaceutical research, and preclinical research. It also discussed the opportunities and opportunities faced by nucleic acid drugs. Challenges were discussed in depth. The experts analyzed it from shallow to deep, from point to surface, and in depth, presenting an academic feast and winning the attention and praise of many participants.
▲ Professor Peng Shuangqing, Chief Scientific Officer of Medicilon, presided over the seminar
The seminar was hosted by Professor Peng Shuangqing, Chief Scientific Officer of Medicilon. Professor Peng pointed out that nucleic acid drugs have the advantages of short research and development cycles, fast target screening, and wide therapeutic areas. They are expected to become the third largest category of drugs after small molecule drugs and antibody drugs , but the barriers to research and development are high. As a result, the Medicilon nucleic acid drug research and development platform, covering drug discovery, pharmaceutical research, and preclinical research, came into being. In addition, Professor Peng said that this seminar aims to further promote the development of nucleic acid drug research in China and break relevant technical bottlenecks.
▲Dr. Ma Xingquan, Senior Vice President of Medicilon's Chemistry Department, gave a report
Subsequently, Dr. Ma Xingquan, Senior Vice President of Medicilon's Chemistry Department, gave a special report on "The Application of Medicinal Chemistry in siRNA Drug Discovery" from the perspective of drug discovery. The report explains the basic structure of nucleic acid drugs, combined with a large number of practical cases, explains the chemical modifications of nucleic acid drugs and commonly used chemical modifications of oligonucleotide drugs in a simple and easy-to-understand manner, and discusses the oligonucleotide delivery strategy, etc., for Drug discovery of nucleic acid drugs has guiding significance.
▲Dr. Wang Jin, Executive Director of Medicilon Preparation Department, gave a report
Dr. Wang Jin, Executive Director of Medicilon Preparation Department, gave a special report on "Introduction to mRNA Drug Design, Process Development and Quality Control" from the perspective of pharmaceutical research. Dr. Wang briefly introduced the development history of mRNA technology, focusing on the key technologies for the preparation of mRNA stock solution. In addition, Dr. Wang also introduced the preparation and delivery mechanism of LNP-mRNA, and looked forward to the development trend of mRNA drugs from the targeted delivery of LNP and the development of inhaled LNP-mRNA vaccines, which has guiding significance for the preparation of mRNA processes.
▲Dr. He Quanren, Senior Vice President of Biopharmacology and Toxicology at Aibo, gave a report
Dr. He Quanren, Senior Vice President of Biopharmacology and Toxicology at Aibo, as an expert in the field of nucleic acid drugs, brought a report on "The Safety of mRNA Delivery Systems" Special Report. Dr. He first raised two major challenges for mRNA drugs, emphasized the importance of delivery systems for mRNA drugs, outlined the considerations for designing drug delivery system , and pointed out that lipid nanoparticles (LNP) are the mainstream delivery system. In addition, Dr. He provided research strategies on the toxicity of nanoparticle delivery systems from aspects such as blood compatibility, immunotoxicity, liver toxicity, and injection site inflammation, providing ideas for further breakthroughs in the technical bottleneck of delivery systems. It is worth mentioning that the mRNA vaccine developed by Aibo Biotech has entered clinical phase III.
▲Dr. Wan Hong, Vice President of Medicilon Pharmacokinetics and Bioanalysis Department, gave a report
Dr. Wan Hong, Vice President of Medicilon Pharmacokinetics and Bioanalysis Department, gave a report on "The Development of RNA Nucleic Acid Drugs" from the perspective of preclinical research. ADME Characteristics and Preclinical Druggability Evaluation" special report briefly introduced the absorption, distribution, metabolism and excretion characteristics of small nucleic acid drugs, as well as the prediction of human PK parameters, and clarified the relationship between drug efficacy and pharmacokinetics. . In addition, Dr. Wan combined with already marketed small nucleic acid drugs to eliminate some blind spots in preclinical research on nucleic acid drugs.
▲Dr. Zeng Xiancheng, Vice President of Medicilon's Preclinical Toxicology Research Department, gave a report
Dr. Zeng Xiancheng, Vice President of Medicilon's Preclinical Toxicology Research Department, gave a speech entitled "Nonclinical Evaluation of Nucleic Acid Drugs" from the perspective of non-clinical safety evaluation. Special report on "Thoughts on Safety Evaluation Strategies".Dr. Zeng emphasized that before evaluating siRNA, one must first fully understand its structure and preparation characteristics. From the two aspects of pharmacodynamics and safety evaluation, combined with the research content and results of siRNA drugs on the market, and a large number of practical cases, the image The research strategies for non-clinical research of nucleic acid drugs are specifically explained, providing practical solutions for preclinical research of nucleic acid drugs.
▲ Dr. Yuan Xudong, founder and CEO of Aikang Pharmaceutical, gave a report
Dr. Yuan Xudong, founder/CEO of Aikang Pharmaceutical, is committed to combining siRNA drugs with inhaled preparations and gave a speech titled "The Development and Delivery of siRNA Drugs" The special report "System Challenges" systematically introduced the development process of siRNA small nucleic acid drugs, Alnylam's R&D pipeline, and deeply analyzed the opportunities faced by the development of new RNA interference drugs. He also shared his insights on siRNA delivery systems and siRNA products, pointing out the direction for further research on nucleic acid drug delivery systems.
▲ Attend the roundtable forum
The collision of ideas produces wisdom, and the exchange of wisdom produces sparks. After the wonderful special report, a roundtable discussion centered on the current status and trends of nucleic acid drug research and development began. Dr. Yingbo, founder/CEO of Aibo Biotech, Dr. Yuan Xudong, founder/CEO of Aikang Pharmaceutical, Dr. Ma Xingquan, senior vice president of Medicilon’s Chemistry Department, Dr. Wan Hong, vice president of Medicilon’s Pharmacokinetics and Bioanalysis Department, etc. attended the meeting "Breaking the R&D of Nucleic Acid Drugs and Ushering in a New Era of Nucleic Acid Drugs" roundtable forum. Professor Peng Shuangqing, Chief Scientific Officer of Medicilon, presided over the event.
Regarding the opportunities and challenges faced by nucleic acid drugs, the guests combined their own experiences to elaborate on the difficulties of nucleic acid drugs from research and development to application at this stage, and shared their insights. As leaders in the field of nucleic acid drugs, Dr. Yingbo and Dr. Yuan Xudong believe that the research and development technology of nucleic acid drugs is innovating and iterating, and are optimistic about future development. They agree that CRO will become a powerful and necessary aid for innovative pharmaceutical companies. Dr. Ma Xingquan and Dr. Wan Hong discussed how CRO can help nucleic acid drugs enter the clinical stage, and expressed their expectation to deepen cooperation in the biomedicine industry chain and jointly "bathe in the fire" to create a brilliant future for China's small nucleic acid drugs.
Innovation occurs in the entire ecosystem and is the internal driving force for the development of medicine. The take-off of nucleic acid drugs requires the comprehensive empowerment of drug discovery, pharmaceutical research, and preclinical research. As a one-stop preclinical biopharmaceutical R&D CRO, Medicilon has long-term focus on preclinical biopharmaceutical R&D. It has successfully built a nucleic acid drug R&D platform and will continue to help global new drug developers jointly meet new opportunities and challenges in the nucleic acid era.
